Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets

Vaccine

Volumn 27, Issue 31, 2009, Pages 4187-4195

  Forrest, Heather L ^a   Khalenkov, Alexey M ^a   Govorkova, Elena A ^a   Kim, Jeong Ki ^a   Del Giudice, Giuseppe ^b   Webster, Robert G ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

H5N1 influenza; MF59 Adjuvant; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA A H5N1 VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; SIALIDASE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FERRET; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MALE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; UPPER RESPIRATORY TRACT; VIRUS GENE; VIRUS SHEDDING; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; FERRETS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED; VIRUS SHEDDING;

EID: 67349207076     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.050     Document Type: Article

References (39)

1. Alexander D.J. Summary of avian influenza activity in Europe, Asia, Africa, and Australasia, 2002-2006. Avian Diseases 51 March (1 (Suppl.)) (2007) 161-166
2. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO; 2008 [cited 2008 May 21]. Available from: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_ 01_24/en/index.html.
3. Webster R.G., and Govorkova E.A. H5N1 influenza-continuing evolution and spread. The New England Journal of Medicine 355 November (21) (2006) 2174-2177
4. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. The New England Journal of Medicine 358 January (3) (2008) 261-273
5. Monto A.S. The threat of an avian influenza pandemic. The New England Journal of Medicine 352 January (4) (2005) 323-325
6. Monto A.S. The role of antivirals in the control of influenza. Vaccine 21 May (16) (2003) 1796-1800
7. Lipsitch M., Cohen T., Murray M., and Levin B.R. Antiviral resistance and the control of pandemic influenza. PLoS Medicine 4 January (1) (2007) e15
8. Hayden F.G., and Pavia A.T. Antiviral management of seasonal and pandemic influenza. The Journal of Infectious Diseases 194 November (Suppl. 2) (2006) S119-S126
9. Smith D.J. Predictability and preparedness in influenza control. Science (New York, NY) 312 April (5772) (2006) 392-394
10. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 February (13-14) (2001) 1732-1737
11. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 August (9587) (2007) 580-589
12. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 June (9272) (2001) 1937-1943
13. Subbarao K., and Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nature Reviews 7 April (4) (2007) 267-278
14. Wood J.M., and Robertson J.S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nature Reviews Microbiology 2 October (10) (2004) 842-847
15. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. Journal of Virology 80 February (4) (2006) 1959-1964
16. Kodihalli S., Goto H., Kobasa D.L., Krauss S., Kawaoka Y., and Webster R.G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. Journal of Virology 73 March (3) (1999) 2094-2098
17. Hoffmann E., Krauss S., Perez D., Webby R., and Webster R.G. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20 August (25-26) (2002) 3165-3170
18. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 April (9415) (2004) 1099-1103
19. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., and Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. The Journal of Infectious Diseases 194 July (2) (2006) 159-167
20. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. The New England Journal of Medicine 354 March (13) (2006) 1343-1351
21. Podda A, Giudice GD. MF59 adjuvant emulsion. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, editors. New generation vaccines, third ed. New York: Marcel Dekker, Inc.; 2004. p. 225-35.
22. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 April (15) (2003) 1687-1693
23. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. The Journal of Infectious Diseases 191 April (8) (2005) 1210-1215
24. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. Journal of Biological Standardization 5 3 (1977) 237-247
25. Reuman P.D., Keely S., and Schiff G.M. Assessment of signs of influenza illness in the ferret model. Journal of Virological Methods 24 April-May (1) (1989) 27-34
26. Reed L.J., and Muench H. A simple method for estimating fifty percent endpoint. American Journal of Hygiene 27 (1938) 493-497
27. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. The Journal of Infectious Diseases 197 March (5) (2008) 667-675
28. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., and Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proceedings of the National Academy of Sciences of the United States of America 102 September (36) (2005) 12915-12920
29. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., and Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunological Reviews 159 October (159) (1997) 105-117
30. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 January (4) (2008) 552-561
31. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. Journal of Immunology 176 May (10) (2006) 6333-6339
32. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. The New England Journal of Medicine 309 July (1) (1983) 13-17
33. Vandepapeliere P., Rehermann B., Koutsoukos M., Moris P., Garcon N., Wettendorff M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23 April (20) (2005) 2591-2601
34. Polhemus M.E., Magill A.J., Cummings J.F., Kester K.E., Ockenhouse C.F., Lanar D.E., et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25 May (21) (2007) 4203-4212
35. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 September (9540) (2006) 991-997
36. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 May (9523) (2006) 1657-1664
37. Del Giudice G., Fragapane E., Bugarini R., Hora M., Henriksson T., Palla E., et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 13 September (9) (2006) 1010-1013
38. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Review of Vaccines 6 October (5) (2007) 699-710
39. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3 1 (2008) e1401